Sales and Marketing. In the fourth quarter 2007, we continued to execute on our sales and marketing strategy, resulting in the entry of our products in 106 new hospitals throughout China. In addition, we experienced more than 51% sales growth in Beijing hospitals, with much of that growth resulting from the successful entry of our EPIAO products in 19 major hospitals in the Beijing military hospital system under management by the Health Administration of the People's Libration Army.
In addition, demonstrating our leadership in pharmaceutical industry best practice in China and as part of our on going commitment to product quality, we have introduced a new pharmacovigilance program. We also initiated the Phase IV program with our innovative class I product, TPIAO, in 2007. As of the end of the fourth quarter, 2007, we reviewed the interim results of the TPIAO program, with no safety issues detected among the 1000 patients who have been treated with TPIAO. We expect to complete the full program for TPIAO phase IV trial by the second quarter of 2009.
In-Licensed Products. We successfully completed all four trials for our in-licensed Iron Sucrose product. As part of our growth strategies, we will continue to analyze additional in-licensing opportunities.
2008 Full Year Guidance
Based on current market and operating conditions, our total net revenue target for the full year 2008 will be between the estimated range of US$30 to US$32 million.
3SBio's senior management will host a conference call at 5:00 am
(Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on Thursday,
February 21, 2008 to discuss its 2007 fourth quarter and full year
financial results and recent business activity. The conference call may be
accessed by calling (US) +1-480-629-90
|SOURCE 3SBio Inc.|
Copyright©2008 PR Newswire.
All rights reserved